Clinical Trials Browser

Has results × Neoplasm Metastasis × eribulin × Clear all

NCT05104866 2026-02-04

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Phase 3 Active not recruiting

732 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Phase 3 Active not recruiting

557 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT02061085 2025-06-08

MERIBEL

Phase 2 Completed

53 enrolled 11 charts

Breast Neoplasms, Ketosis, Neoplasm Metastasis

NCT02915744 2023-04-14

ATTAIN

Phase 3 Completed

178 enrolled 37 charts

Breast Neoplasms, Carcinoma, Neoplasm Metastasis

NCT01596751 2020-07-17

Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

Phase 1/2 Completed

67 enrolled 19 charts

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01961544 2016-10-07

ESKIMO

Phase 4 Completed

101 enrolled 6 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00278993 2014-07-14

Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

Phase 2 Completed

108 enrolled 11 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT00069264 2011-12-20

Study of E7389 in Patients With Advanced Solid Tumors

Phase 1 Completed

33 enrolled 8 charts

Neoplasm Metastasis, Neoplasms